Follow Flash Finance FollowTelegram

Integris Medtech Sets IPO Timeline to Raise Up to Rs 3000 Crore Starting November 27

Markets By Flash Finance desk (written with AI assistance) Editor: Kokila

Integris Medtech Sets IPO Timeline to Raise Up to Rs 3000 Crore Starting November 27

Gurugram-headquartered medical products and laboratory solutions provider Integris Medtech Limited is poised to enter the Indian primary market with an initial public offering (IPO) expected to raise between ₹2,500 crore and ₹3,000 crore. According to market timelines and draft disclosures, the public issue is scheduled to open for subscription on November 27, 2026, and close on December 1, 2026.

The issue will list on both the BSE and the National Stock Exchange (NSE), with tentative equity allotment scheduled for December 2, 2026, and listing anticipated on December 4, 2026.

Issue Structure and Selling Shareholders

The public offer will be executed as a book-built issue consisting of both a fresh capital raise and an Offer for Sale (OFS) by existing shareholders:

  • Fresh Issue: The company plans to issue fresh equity to raise upfront capital, with draft filings outlining a fresh issue component of up to ₹600 crore.
  • Offer for Sale (OFS): The secondary component comprises an OFS of up to 1.08 crore equity shares with a face value of ₹1 each. Promoter and investor selling shareholders participating in the divestment include Evercure Holdings Pte. Ltd., Gurmit Singh Chugh, and Punita Sharma.
  • Price Band and Lot Size: While the formal price band and minimum bidding lot size are slated to be announced in the run-up to the opening date, the retail quota is earmarked at 10%, non-institutional investors (NII) at 15%, and qualified institutional buyers (QIB) at 75%.

Utilisation of IPO Proceeds

A central objective of the fresh capital raise is deleveraging across the company's operating structure. Integris Medtech intends to deploy roughly 85% of the net proceeds from the fresh issue toward full or partial repayment or prepayment of debt availed by its subsidiaries.

Targeted entities for debt reduction include wholly owned subsidiaries such as Translumina Therapeutics Private Limited, Transhealth Private Limited, and HaleMed Medical Private Limited, alongside step-down subsidiaries including CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd., and Chemoscience Pte Ltd. The remaining capital will be deployed toward general corporate purposes.

Business Footprint and Market Significance

Founded in 2008, Integris Medtech (formerly known as Integris Health Private Limited) operates across two primary business verticals: Cardiovascular Devices and Laboratory Solutions. The firm develops, manufactures, and commercialises a range of interventional devices, in-vitro clinical diagnostics, and scientific laboratory equipment.

The company maintains manufacturing capabilities across India, Germany, and the Netherlands, exporting products to more than 65 international markets across Europe, Southeast Asia, and the domestic Indian healthcare ecosystem.

For Indian market participants, the listing offers targeted exposure to the high-barrier medtech manufacturing sector, which has traditionally seen limited representation on domestic exchanges compared to standard pharmaceutical and hospital operators.

Tags: Integris MedtechBSENSESEBIHealthcare DevicesPrimary Market

← Back to All News
FollowTelegram
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI